Attached files
file | filename |
---|---|
EX-3.2 - EXHIBIT 3.2 - TomoTherapy Inc | c13755exv3w2.htm |
EX-2.1 - EXHIBIT 2.1 - TomoTherapy Inc | c13755exv2w1.htm |
EX-99.2 - EXHIBIT 99.2 - TomoTherapy Inc | c13755exv99w2.htm |
EX-10.1 - EXHIBIT 10.1 - TomoTherapy Inc | c13755exv10w1.htm |
EX-99.1 - EXHIBIT 99.1 - TomoTherapy Inc | c13755exv99w1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 7, 2011 (March 6, 2011)
TOMOTHERAPY INCORPORATED
(Exact name of registrant as specified in its charter)
Wisconsin | 001-33452 | 39-1914727 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
1240 Deming Way Madison, Wisconsin |
53717 |
|
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code: (608) 824-2800
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
þ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
þ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01. Entry Into a Material Definitive Agreement
On March 6, 2011,
TomoTherapy Incorporated, a Wisconsin corporation (the Company), entered into an Agreement and
Plan of Merger (the Merger Agreement) with Accuray Incorporated, a Delaware corporation (Parent), and
Jaguar Acquisition, Inc., a Wisconsin corporation and wholly owned subsidiary of Parent (Merger
Sub).
Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of certain closing
conditions, Merger Sub will merge with and into the Company, with the Company surviving as a wholly
owned subsidiary of Parent (the Merger). At the effective time of the Merger (the Effective
Time), each issued and outstanding share of common stock of the Company, par value $0.01 per share
(Company Common Stock) (other than shares held in the treasury of the Company or owned, directly
or indirectly, by Parent, Merger Sub or any subsidiary of the Company) will be converted into the
right to receive (i) $3.15 in cash, without interest, and (ii) 0.1648 shares of the common stock of
Parent, par value $0.001 per share (Parent Common Stock).
At the Effective Time, each outstanding option to purchase shares of Company Common Stock (Company
Stock Option) will be converted into an option to purchase shares of Parent Common Stock (a
Parent Option), on the same terms and conditions as were applicable immediately prior to the
Effective Time. The number of shares of Parent Common Stock subject to each Parent Option will be
equal to the number of shares of Company Common Stock subject to the related Company Stock Option
immediately prior to the Effective Time multiplied by the Company Stock Option Exchange Ratio,
rounded down, if necessary, to the nearest whole share of Parent Common Stock, and such Parent
Option will have an exercise price per share (rounded up to the nearest whole cent) equal to the
exercise price per share of Company Common Stock divided by the Company Stock Option Exchange
Ratio,
in each case subject to adjustment in order to comply with certain provisions of the
Internal Revenue Code of 1986, as amended, and to ensure that the number of shares of
Parent Common Stock subject to Parent Options, together with all shares of Parent
Common Stock issuable in the Merger, is below certain thresholds.
Company Stock Option Exchange Ratio is defined as the sum of (a) $3.15 divided by the
volume weighted average of the daily
closing prices per share of Parent Common Stock on the Nasdaq Global Select Market for
the five consecutive trading days ending on and including the trading day immediately preceding the
Effective Time plus (b) the number of shares of Parent Common Stock to which each share of Company
Common Stock is entitled in the Merger.
At the Effective Time, each outstanding share of restricted stock of the Company (other than shares
held in the treasury of the Company or owned, directly or indirectly, by Parent, Merger Sub or any
subsidiary of the Company) will be converted into the right to receive (A) $3.15 in cash, without
interest, and (B) 0.1648 shares of Parent Common Stock (such amount in cash and stock, the Merger
Consideration). However, the stock portion of the Merger Consideration payable
to holders of shares of restricted stock of the Company will continue to have the same
vesting and forfeiture provisions and the cash portion of the Merger Consideration payable
to holders of shares of restricted stock of the Company will not be payable until
the date such restricted shares would have become vested under the vesting
schedule in place for such shares immediately prior to the Effective Time (subject to the same
terms and conditions, including any vesting or forfeiture provisions or repurchase rights, but
taking into account any acceleration thereof provided for in the applicable plan, related award
document or any other agreement).
Completion of the Merger is subject to certain closing conditions, including the approval of the
Companys shareholders, receipt of antitrust approval, receipt by the Company of certain
third-party consents and the deposit by the Company of $65,000,000 in cash into a Company account
with the exchange agent.
The Merger Agreement contains certain termination rights of the Company and Parent. Upon a
termination of the Merger Agreement under certain circumstances, the Company will be required to
pay a termination fee of $8,000,000. If the Merger Agreement is terminated by the Company or
Parent under certain other circumstances, the Company will be required to pay expenses incurred by
Parent or Merger Sub or on their behalf, in an amount not to exceed $1,500,000. In no event will
the Company be required to pay both the termination fee and Parents and Merger Subs expenses.
Concurrently with the execution of the Merger Agreement, all of the Companys executive officers
and directors entered into a Support Agreement with Parent, pursuant to which they agreed, in their
capacity as shareholders of the Company, to vote the shares beneficially owned by them in favor of
the Merger, which shares represented approximately 11% of the outstanding shares of Company Common
Stock as of February 28, 2011.
The foregoing summaries of the Merger Agreement and the Support Agreement, and the transactions
contemplated thereby, do not purport to be complete and are subject to, and qualified in their
entirety by, the full text of such agreements, which are filed herewith as Exhibits 2.1 and 99.1,
respectively, and are incorporated herein by reference. The Merger Agreement has been included to
provide investors with information regarding its terms. It
contains certain representations, warranties and covenants of the Company, which were made for
purposes of the Merger Agreement and are subject to qualifications and limitations agreed to by the
parties. In addition, certain representations and warranties were made as of a specific date, may
be subject to a contractual standard of materiality different from what might be viewed as material
to investors or may have been used for purposes of allocating risk between the respective parties
rather than establishing matters as facts. Moreover, information concerning the subject matter of
the representations, warranties and covenants may change after the date of the Merger Agreement,
which subsequent information may or may not be fully reflected in public disclosures by the Company
or Parent. Accordingly, investors should not rely on the representations, warranties or covenants
in the Merger Agreement as characterizations of the actual state of facts about the Company.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers
(e)
Employment Agreement Amendment. On March 6, 2011, the Company and Brenda S. Furlow, Vice President
and General Counsel of the Company, entered into a Second Amendment to Employment Agreement (the
Amendment). The Amendment provides for tax gross-up payments with respect to excise tax
liability, if any, under Internal Revenue Code Section 4999 related to Section 280G excess
parachute payments.
The foregoing summary of the Amendment does not purport to be complete and is subject to, and
qualified in its entirety by, the full text of the Amendment, which is filed herewith as Exhibit
10.1, and is incorporated herein by reference.
2007 Award Determination. On March 6, 2011, in accordance with the Companys 2007 Equity Incentive
Plan, as amended (the 2007 Plan), the Board of Directors of the Company approved certain
modifications to the treatment of outstanding options and awards under the 2007 Plan. As a result,
if any person, who, as of immediately prior to the Effective Time is an employee, officer or
director of the Company, then ceases to be employed by, or to provide services to, the Company and
its affiliates due to a termination of such employment or services by the Company or its affiliates
without Cause within one year after the Effective Time, all of such persons awards that were
outstanding under the 2007 Plan as of the Effective Time will immediately become fully vested and,
in the case of outstanding options to purchase Company Common Stock, become exercisable. For these
purposes, Cause is defined as a termination of employment or service due to the occurrence of one
or more of the events set forth below which, with respect to an event specified in clause (A) or
(E) below, if curable, the holder has not cured within 14 days after such holder has received
written notice from the Company, Parent or their affiliates specifying with reasonable
particularity such occurrence: (A) the holders failure or willful refusal to comply in any
material respect with lawful Company employment policies or directives, (B) the holders material
breach of the Confidentiality Agreement and Assignment of Inventions Agreement or similar agreement
between the holder and Parent or the Company, (C) the holders commission of willful misconduct or
an act of fraud, theft or embezzlement against the Company, Parent or any of their affiliates, (D)
the holders conviction or plea of nolo contendere to any felony or any other crime involving moral
turpitude or (E) the holders repeated failure to substantially perform the duties and
responsibilities of the holders position. The Board of Directors of the Company further
determined that for purposes of the foregoing, the Company shall be deemed to have terminated the
services of each member of the Board without Cause as of the Effective Time.
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
On March 6, 2011, the Board of Directors of the Company approved an amendment to Section 2.01 of
the Companys Amended and Restated Bylaws, effective immediately. As amended, Section 2.01
provides as follows:
The annual shareholders meeting for the purpose of electing directors and
transacting such other business as may properly come before the meeting shall be
held at such date and time as may from time to time be designated by resolution
passed by the board of directors.
2
Prior to the amendment, the Companys Amended and Restated Bylaws provided that the Companys
annual shareholders meeting must be held within 30 days of the first Friday of April each year.
A complete copy of the Amended and Restated Bylaws, as amended, is included as Exhibit 3.2 to this
Current Report on Form 8-K and incorporated herein by reference.
Item 7.01. Regulation FD Disclosure
On March 7, 2011, the Company issued a press release announcing the execution of the Merger
Agreement. A copy of the press release is furnished herewith as Exhibit 99.2 and is incorporated
herein by reference.
The information contained in, or incorporated into, this Item 7.01, including Exhibit 99.2 attached
hereto, is being furnished and shall not be deemed filed for the purposes of Section 18 of the
Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference into any registration statement or
other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference to such filing.
Additional Information about the Merger and Where to Find It
In connection with the proposed transaction, Parent will file with the Securities and Exchange
Commission ) (the SEC) a registration statement on Form S-4 and the Company will mail a proxy
statement to its shareholders, and each will also be filing other documents regarding the proposed
transaction with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS ARE URGED TO
READ THE PROXY STATEMENT REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS
CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION ABOUT THE PROPOSED TRANSACTION. The final proxy statement will be mailed to the
Companys shareholders. Shareholders will be able to obtain a free copy of the proxy statement, as
well as other filings containing information about the Company and Parent, without charge, at the
SECs Internet site (http://www.sec.gov). Copies of the proxy statement and the filings with the
SEC that will be incorporated by reference in the proxy statement can also be obtained, without
charge, by directing a request to Brenda S. Furlow, Vice President and General Counsel, TomoTherapy
Incorporated, 1212 Deming Way, Madison, Wisconsin, 53717, (608) 824-2800.
Participants in the Solicitation
The Company and its directors and executive officers and other persons may be deemed to be
participants in the solicitation of proxies in respect of the proposed transaction. Information
regarding the Companys directors and executive officers is available in the Companys proxy
statement for its 2010 annual meeting of shareholders and the Companys Annual Report on Form 10-K
for the year ended December 31, 2010, which were filed with the SEC on March 22, 2010 and March 3,
2011, respectively. Other information regarding the participants in the proxy solicitation and a
description of their direct and indirect interests, by security holdings or otherwise, will be
contained in the proxy statement and other relevant materials to be filed with the SEC when they
become available.
3
Item 9.01. Financial Statements and Exhibits
Number | Description | |||
2.1 | Agreement and Plan of Merger, dated as of March 6, 2011, among Parent, Merger Sub and the
Company* |
|||
3.2 | Amended and Restated Bylaws of the Company, as amended on March 6, 2011 |
|||
10.1 | Second Amendment to Employment Agreement, dated as of March 6, 2011, by and between the
Company and Brenda S. Furlow |
|||
99.1 | Support Agreement, dated as of March 6, 2011, among Parent and the shareholders party thereto |
|||
99.2 | Press release issued by the Company on March 7, 2011 |
* | Pursuant to Regulation S-K Item 601(b)(2), the exhibits and schedules have been omitted. The Company agrees to furnish supplementally a copy of any of such materials to the Securities and Exchange Commission upon request. |
4
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
TOMOTHERAPY INCORPORATED |
||||
By: | /s/ Thomas E. Powell | |||
Name: | Thomas E. Powell | |||
Title: | Chief Financial Officer and Treasurer |
Date: March 7, 2011
EXHIBIT INDEX
Number | Description | |||
2.1 | Agreement and Plan of Merger, dated as of March 6, 2011, among Parent, Merger Sub and the
Company* |
|||
3.2 | Amended and Restated Bylaws of the Company, as amended on March 6, 2011 |
|||
10.1 | Second Amendment to Employment Agreement, dated as of March 6, 2011, by and between the
Company and Brenda S. Furlow |
|||
99.1 | Support Agreement, dated as of March 6, 2011, among Parent and the shareholders party thereto |
|||
99.2 | Press release issued by the Company on March 7, 2011 |
* | Pursuant to Regulation S-K Item 601(b)(2), the exhibits and schedules have been omitted. The Company agrees to furnish supplementally a copy of any of such materials to the Securities and Exchange Commission upon request. |